Novel Organometallic Complex for Cancer (Case 1973)



Brown University

Providence, RI

Brief Description:      


This invention comprises of the synthesis, biological evaluations and pharmaceutical compositions of synthetic organometallic complexes known as Metallosalophenes (MSP). Included are novel compositions of metal-chelating analogues, and method of their preparation and use. It has now been discovered that a number of MSPs display anticancer activity in models of various cultured solid tumor cancer cells such as neuroblastoma, breast, ovarian, prostate, pancreatic and liver and in other nonsolid human tumors as well as in vivo models. When intra-peritoneally applied to rats Fe-SP did not show any systemic toxicity at concentrations that in preliminary trials were determined to be chemotherapeutic relevant doses in a rat ovarian cancer cell model. Further studies were conducted on the systemic toxicity of Fe-SP when applied in rats as a model system. When applied in rats Fe-SP neither revealed acute toxicity (at concentrations, 5.5 mg/kg for IP administration, 2000 mg/kg for oral administration; present study) nor systemic toxicity (at concentrations 4 mg/kg) that all exceeded the chemotherapeutic relevant doses (1 mg/kg body weight) of Fe-SP determined in a study trial in a rat ovarian cancer cell model. In tumors of Fe-SP treated animals, but not in tumors of untreated rats, apoptotic events, such as caspase-3 activation and PARP deactivation occurred. These studies support the potential of this therapeutic drug as well as novel analogues and derivatives to treat such tumors in vivo.




US patent 8,252,780 is issued (08/28/2012)


Drug Design, Development and Therapy 2009:3

PLoS ONE, May 2008, Volume 3, Issue 5, e2303

Patent Information:
For Information, Contact:
Margaret Shabashevich,
Manager of Operations
Technology Ventures Office
Brown University
Rakesh Singh
Laurent Brard
Satyan Kalkunte
Onur Alpturk
Robert Strongin
© 2017. All Rights Reserved. Powered by Inteum